<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1179">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04416893</url>
  </required_header>
  <id_info>
    <org_study_id>COVILLE2</org_study_id>
    <nct_id>NCT04416893</nct_id>
  </id_info>
  <brief_title>Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children (COVILLE2 )</brief_title>
  <acronym>COVILLE2</acronym>
  <official_title>Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care-Part 2 After the Lifting of the Lockdown</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Clinique Th√©rapeutique Infantile du val de Marne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GPIP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GFRUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      France and in particular the paris area was one of the countries most affected by the
      pandemic Covid19.

      School closures and a generalized lockdown of the population were instituted in France from
      17 March 2020 to 10 May 2020. Schools and nurseries have reopened partially since 11 May
      2020. From 2 June, this reopening is more widespread. By combining the search for SARS-Cov2
      viruses by PCR and micro-method serology we will be able to evaluate both the infection at a
      given time and also older contact with SARS-CoV2.

      The temporal knowledge of the prevalence of SARS-Cov2 carriage and the serological status
      (IgM and IgG) after return to the community are crucial information to evaluate the speed of
      spread of the virus in children. This is the objective of COVILLE2, phase 2 of the COVILLE
      study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 7, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of asymptomatic children or children with mild respiratory symptoms</measure>
    <time_frame>At inclusion</time_frame>
    <description>Proportion of asymptomatic children or children with mild respiratory symptoms (mildly-symptomatic children) with a positive SARS-Cov2 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) on rhino pharyngeal swab or/and IgM/IgG positive serology in Paris area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cov2-SARS cases by age</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cov2-SARS cases by symptoms</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>At inclusion</time_frame>
    <description>The viral load of children with SARS-Cov2 positive Reverse Transcriptase Polymerase Chain Reaction depending on the symptoms and the age of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-SARS-CoV-2 antibodies (IgM and IgG) by the rapid serological test</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">630</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Children under 15 years of age in a community</arm_group_label>
    <description>Children under 15 years of age in a community : kindergarten, school, college, holiday center, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RT-PCR SARS-Cov2</intervention_name>
    <description>nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR</description>
    <arm_group_label>Children under 15 years of age in a community</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sars-Cov2 serology</intervention_name>
    <description>A microsample of blood will be taken for serology</description>
    <arm_group_label>Children under 15 years of age in a community</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children under 15 years of age in a community (kindergarten, school, college, holiday
        centre, etc.).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth to 15 years old

          -  taking over the community (kindergarten, school, college, holiday centre, etc.) for at
             least 1 week

        Exclusion Criteria:

          -  refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RT-PCR SARS-CoV-2</keyword>
  <keyword>Serology SARS-CoV-2</keyword>
  <keyword>Children</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

